GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (STU:TE1) » Definitions » Additional Paid-In Capital

Bio-Techne (STU:TE1) Additional Paid-In Capital : €727 Mil(As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bio-Techne Additional Paid-In Capital?


Bio-Techne's quarterly additional paid-in capital increased from Sep. 2023 (€700 Mil) to Dec. 2023 (€701 Mil) and increased from Dec. 2023 (€701 Mil) to Mar. 2024 (€727 Mil).

Bio-Techne's annual additional paid-in capital increased from Jun. 2021 (€444 Mil) to Jun. 2022 (€617 Mil) and increased from Jun. 2022 (€617 Mil) to Jun. 2023 (€666 Mil).

Bio-Techne Additional Paid-In Capital Historical Data

The historical data trend for Bio-Techne's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Additional Paid-In Capital Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 280.37 373.44 443.56 617.23 665.98

Bio-Techne Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 667.86 665.98 699.57 700.84 727.19

Bio-Techne Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Bio-Techne Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne (STU:TE1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (STU:TE1) » Definitions » Additional Paid-In Capital
Comparable Companies
UTHR ROIV INCY LEGN VKTX SRPT CERE ASND RPRX EXEL OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
TECH:USA TE1:Germany T1CH34:Brazil
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Website
https://www.bio-techne.com
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (STU:TE1) Headlines

No Headlines